Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailor-made management versus routine care in newly diagnosed DMARD-naive rheumatoid arthritis
NL-OMON59786Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of golimumab in rheumatoid arthritis (RA), sponsored by Erasmus MC. Primary endpoints: Proportion of patients using a biologic or targeted synthetic DMARD after 10 months, Disease activity score over time and 1 more. Started Oct 2024; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON59786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59786.